Phase III Randomized Study of Elective Nodal Irradiation Plus Erlotinib Combined with Chemotherapy for Esophageal Squamous Cell Carcinoma.

Shi Xiu Wu,Honglei Luo,Lvhua Wang,Xuebang Zhang,Bing Xia,Congying Xie,Ming Chen,Conghua Xie,Xiuhua Bian,Wei Hu,Anping Zheng,Jiancheng Li,Duojie Li,Ruifei Xie,Gang Li
DOI: https://doi.org/10.1200/jco.2016.34.15_suppl.4048
IF: 45.3
2016-01-01
Journal of Clinical Oncology
Abstract:4048 Background: The addition of anti-EGFR therapy to chemoradiotherpay in the treatment of unresectable esophageal squamous cell carcinoma (ESCC) is not well defined, as well as the role of elective nodal irradiation (ENI). This phase III trial was designed to determine whether the addition of erlotinib and/or ENI to concurrent conventional chemoradiotherapy containing cisplatin/paclitaxel (CP) improved survival. Methods: This study was a 2x2 factorial design, with erlotinib and ENI as factors. We randomized Chinese patients with ESCC to: (A) ENI/CP/erlotinib; (B) ENI/CP; (C) conventional-field irradiation (CFI)/CP/erlotinib; (D) CFI/CP. The primary endpoint was overall survival (OS); secondary endpoints included progression-free survival, local-regional failure rate, and toxicity. Three hundred and forty-four patients and 242 events were needed for 85% power to detect a hazard ratio (HR) of 0.76 (2-year OS rate from 35% to 45% for each factor) if no interaction between the two factors was observed. Results: From December 2007 to December 2014, 352 patients were recruited. Median follow-up was 16.5 months for all patients at this analysis. There were no significant interactions between the two factors of ENI and erlotinib (P = 0.999). Two-year OS rate and median OS was 54% and 35.4 months for ENI (A+B) versus 42% and 20.5 months for CFI (C+D; HR = 0.69; 95% CI, 0.52 to 0.91; P = 0.008), respectively. Two-year OS rate and median OS was 52% and 24.9 months for erlotinib (A+C) versus 44% and 20.9 months for control (B+D; HR = 0.77; 95% CI, 0.57 to 1.00; P = 0.049), respectively. Patients treated with ENI plus erlotinib (A) achieved a 2-year OS rate of 58% and a median OS of 47.2 months. Hematologic toxicities grade 3 or above were the most common adverse events. Erlotinib was associated with a higher rate of all-grade rash events. Conclusions: Compared with conventional chemoradiotherapy, the addition of either ENI or erlotinib significantly improved survival among Chinese patients with ESCC, with the best of benefits in those treated with ENI plus erlotinib. The incidence rates of adverse-event were acceptable in this study. Clinical trial information: NCT00686114.
What problem does this paper attempt to address?